A financial fraud complaint has been lodged against the producers of the 2023 Malayalam film “RDX Robert Dony Xavier,” directed by Nahas Hidayath. The complaint, filed by Anjana Abraham from Tripunithura, alleges that producers Sophia Paul and James Paul failed to distribute the promised profit margins to stakeholders, despite the film’s commercial success.
Abraham claims she invested Rs. 6 crore in the production, expecting a full return on her investment plus a 30% share of the total profits. However, she asserts that she only received her initial investment back after repeated requests.
Furthermore, she alleges that the producers did not inform her about the revenue generated from the film’s satellite rights, raising concerns about transparency and accountability in the financial dealings surrounding the film.
The complaint has led to an investigation by the police, following a directive from the Tripunithura First Class Magistrate Court. This incident mirrors similar allegations made against the producers of another recent Malayalam hit, “Manjummel Boys,” where investors claimed they were also cheated out of their promised profit shares.
“RDX Robert Dony Xavier” has been well-received at the box office, noted for its engaging storyline and strong performances by actors including Antony Varghese, Shane Nigam, and Neeraj Madhav. The ongoing investigation into the financial practices of its producers has raised questions about the integrity of film financing in the industry.
As the case unfolds, it highlights the growing scrutiny of financial arrangements in the Malayalam film sector, particularly concerning investor rights and profit-sharing agreements.
Meanwhile in Bollywood, a financial dispute has arisen between publicist Dale Bhagwagar and emerging actor and doctor Samarpan Singh from Ludhiana. Despite multiple reminders, Dr. Singh has not settled an outstanding payment of Rs. 12,000 for personal PR services.
The services are said to include promoting Dr. Singh’s acting career and arranging media coverage. The issue stems from a discrepancy in the deduction of TDS from Dr. Samarpan Singh’s account by Deep Pharmacy, an affiliate of Deep Hospital in Ludhiana.
The publicist has emphasized the modest amount and expressed disappointment over the dispute, hinting at possible legal action or involving industry bodies and writing a request for help to political parties like Shiromani Akali Dal from Punjab if the issue remains unresolved. Dr. Samarpan Singh and his representatives have not commented on the allegations yet.